The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
Age range
25 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Participant retention rate
Timeframe: Screening, Visit #1
Participant retention rate
Timeframe: Baseline Assessments, Visit #2
Participant retention rate
Timeframe: Preparatory Session #1, Visit #3 (on study day (-)14; 14 days prior to dosing)
Participant retention rate
Timeframe: Preparatory Session #2, Visit #4 (on study day (-) 7; 7 days prior to dosing)
Participant retention rate
Timeframe: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Participant retention rate
Timeframe: Day of drug administration, Visit #6 (on study day 0)
Participant retention rate
Timeframe: 1-Day post drug administration integration session, Visit #7
Participant retention rate
Timeframe: 7-Day post drug administration integration session, Visit #8
Participant retention rate
Timeframe: 30-days post drug administration follow-up (Follow-up #1), Visit #9
Participant retention rate
Timeframe: 60-days post drug administration follow-up (Follow-up #2), Visit #10
Participant retention rate
Timeframe: 120-days post drug administration follow-up (Follow-up #3), Visit #11 (Final visit)
Preliminary efficacy of psilocybin on methamphetamine abstinence
Timeframe: Screening, Visit #1
Preliminary efficacy of psilocybin on methamphetamine abstinence
Timeframe: Day of drug administration, Visit #6 (on study day 0)
Preliminary efficacy of psilocybin on methamphetamine abstinence
Timeframe: 120 days post drug administration (Follow up #3), Visit #11(final visit)
Preliminary efficacy of psilocybin on methamphetamine abstinence
Timeframe: Screening, Visit #1
Preliminary efficacy of psilocybin on methamphetamine abstinence
Timeframe: 30 day post drug administration (Follow up #1), Visit #9
Preliminary efficacy of psilocybin on methamphetamine abstinence
Timeframe: 60 day post drug administration (Follow up #2), visit #10
Preliminary efficacy of psilocybin on methamphetamine abstinence
Timeframe: 120 days post drug administration (Follow up #3), visit #11
Mystical experiences associated with psilocybin administration
Timeframe: Day of drug administration, Visit #6 (on study day 0)
Challenging experiences associated with psilocybin administration
Timeframe: Day of drug administration, Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Timeframe: Baseline - Visit #2
Physiological responses to psilocybin administration
Timeframe: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Physiological responses to psilocybin administration
Timeframe: Day of drug administration(hourly) - Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Timeframe: Post-session monitoring day of drug administration - Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Timeframe: Baseline - Visit #2
Physiological responses to psilocybin administration
Timeframe: Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing)
Physiological responses to psilocybin administration
Timeframe: Day of drug administration(hourly) - Visit #6 (on study day 0)
Physiological responses to psilocybin administration
Timeframe: Post-session monitoring day of drug administration - Visit #6 (on study day 0)